Acta Neuropathologica Communications (2019-10-01)

Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment

  • Pascal Laforêt,
  • Michio Inoue,
  • Evelyne Goillot,
  • Claire Lefeuvre,
  • Umut Cagin,
  • Nathalie Streichenberger,
  • Sarah Leonard-Louis,
  • Guy Brochier,
  • Angeline Madelaine,
  • Clemence Labasse,
  • Carola Hedberg-Oldfors,
  • Thomas Krag,
  • Louisa Jauze,
  • Julien Fabregue,
  • Philippe Labrune,
  • Jose Milisenda,
  • Aleksandra Nadaj-Pakleza,
  • Sabrina Sacconi,
  • Federico Mingozzi,
  • Giuseppe Ronzitti,
  • François Petit,
  • Benedikt Schoser,
  • Anders Oldfors,
  • John Vissing,
  • Norma B. Romero,
  • Ichizo Nishino,
  • Edoardo Malfatti

Journal volume & issue
Vol. 7, no. 1
pp. 1 – 16


Read online

Abstract Glycogen storage disorder type III (GSDIII), or debranching enzyme (GDE) deficiency, is a rare metabolic disorder characterized by variable liver, cardiac, and skeletal muscle involvement. GSDIII manifests with liver symptoms in infancy and muscle involvement during early adulthood. Muscle biopsy is mainly performed in patients diagnosed in adulthood, as routine diagnosis relies on blood or liver GDE analysis, followed by AGL gene sequencing. The GSDIII mouse model recapitulate the clinical phenotype in humans, and a nearly full rescue of muscle function was observed in mice treated with the dual AAV vector expressing the GDE transgene. In order to characterize GSDIII muscle morphological spectrum and identify novel disease markers and pathways, we performed a large international multicentric morphological study on 30 muscle biopsies from GSDIII patients. Autophagy flux studies were performed in human muscle biopsies and muscles from GSDIII mice. The human muscle biopsies revealed a typical and constant vacuolar myopathy, characterized by multiple and variably sized vacuoles filled with PAS-positive material. Using electron microscopy, we confirmed the presence of large non-membrane bound sarcoplasmic deposits of normally structured glycogen as well as smaller rounded sac structures lined by a continuous double membrane containing only glycogen, corresponding to autophagosomes. A consistent SQSTM1/p62 decrease and beclin-1 increase in human muscle biopsies suggested an enhanced autophagy. Consistent with this, an increase in the lipidated form of LC3, LC3II was found in patients compared to controls. A decrease in SQSTM1/p62 was also found in the GSDIII mouse model. In conclusion, we characterized the morphological phenotype in GSDIII muscle and demonstrated dysfunctional autophagy in GSDIII human samples. These findings suggest that autophagic modulation combined with gene therapy might be considered as a novel treatment for GSDIII.